This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk
LOKELMA (sodium zirconium cyclosilicate) is indicated for the treatment of hyperkalaemia in adult patients.
Hyperkalaemia can be a major burden for people living with CKD or HF, including poor physical health, and an increased risk of hospitalisation* and death.†10-13 For patients on RAASi therapy, there is an increased risk of hyperkalaemia, which can lead to their therapy being reduced or withdrawn.8,9,14 This can increase the risk of all-cause mortality and adverse cardiorenal outcomes.5,9,15
*Increases the risk of hospitalisation in patients with HF with/without CKD.
†Higher all-cause mortality in CKD and HF patients who have hyperkalaemia vs those with no hyperkalaemia.
With updates in 2022 to the NICE TA599 guidance, LOKELMA is recommended and available in both primary and secondary care.16 Following specialist initiation, prescription management can be continued in primary care.16 This means that you can now implement this treatment into your integrated care system (ICS).
By taking action, you can optimise RAASi therapy for your eligible patients.
Take a look at our interactive e-book that delves into the clinical and personal impact of hyperkalaemia on patients, showing how you can use LOKELMA to effectively manage hyperkalaemia and maintain optimal RAASi therapy for cardiorenal protection in patients with CKD or HF.
10 min read
Many primary and secondary care healthcare professionals are taking action with LOKELMA to manage chronic hyperkalaemia. Watch these videos to hear what they have to say about their experiences in practice and the importance of providing holistic care within a multidisciplinary team to improve patient outcomes.
Explore the interplay between primary and secondary care from Dr Smeeta Sinha’s perspective, as they provide guidance on optimal management of patients with hyperkalaemia.
Discover the role of a heart failure specialist nurse in hyperkalaemia management and how Barbara Byrne works with primary care to support patients throughout their treatment journey.
Hear from Dr Naresh Kanumilli as they describe their role in hyperkalaemia management and RAASi therapy maintenance, including how they work with secondary care colleagues, and how you can apply this in practice.
Explore additional practical resources to help you implement LOKELMA in your clinical practice
For your eligible patients with CKD/HF and hyperkalaemia, consider LOKELMA and think about how your role in primary care could make a difference.
CKD=chronic kidney disease; GP=general practitioner; HF=heart failure; NICE=National Institute for Health and Care Excellence; RAASi=renin-angiotensin-aldosterone system inhibitor.
GB-57054 | DOP March 2025
This website is intended for UK Healthcare professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
